EHA 2021 | Benefits of pelabresib with ruxolitinib for treatment naïve myelofibrosis
Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of pelabresib in combination with ruxolitinib for treatment naïve myelofibrosis. Myelofibrosis patients in Arm 2 of the MANIFEST (NCT04603495) Phase II study of pelabresib for anemia associated with myelofibrosis were not achieving adequate benefit from treatment with ruxolitinib, so were treated with pelabresib as add-on. In transfusion dependent (TD) patients, 36% of patients achieved transfusion independence (TI). In non-TD patients, 17.4% of patients achieved a mean hemoglobin (Hgb) increase ≥1.5g/dL sustained over a 12-week transfusion-free period. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
